Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Terapevticheskii Arkhiv|February 1, 2019
Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practiceO V Knyazev, A V Kagramanova, A A Lishchinskaya, et al.Terapevticheskii Arkhiv|October 26, 2022
[Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy]O V Knyazev, S G Khomeriki, A V Kagramanova, et al.Terapevticheskii Arkhiv|September 22, 2012
[Optimization of cell therapy in patients with inflammatory bowel diseases]L B Lazebnik, O V Knyazev, A I Parfenov, et al.Terapevticheskii Arkhiv|April 16, 2025
[Prevention of venous thromboembolic complications in patients with ulcerative colitis]A A Lishchinskaya, O V Knyazev, A V Kagramanova, et al.Terapevticheskii Arkhiv|February 1, 2019
Stem Cell Therapy for Perianal Crohn's DiseaseO V Knyazev, N A Fadeeva, A V Kagramanova, et al.Terapevticheskii Arkhiv|October 26, 2022
[Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn's disease when switching from the original infliximab to its biosimilars]O V Knyazev, M Y Zvyaglova, A V Kagramanova, et al.Terapevticheskii Arkhiv|June 30, 2020
[Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation]O V Knyazev, T V Shkurko, A V Kagramanova, et al.Terapevticheskii Arkhiv|April 29, 2014
[Value of adhesion molecules for evaluating the efficiency of therapy for ulcerative colitis and Crohn's disease]A I Parfenov, O N Boldyreva, I N Ruchkina, et al.Terapevticheskii Arkhiv|September 17, 2016
[Long-term infliximab therapy for ulcerative colitis in real clinical practice]O V Knyazev, A I Parfenov, A V Kagramanova, et al.Terapevticheskii Arkhiv|February 1, 2019
Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapyO V Knyazev, A V Kagramanova, N A Fadeeva, et al.Pageof 4